Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simmitecan Monotherapy and Combination in Advanced Solid Tumors
NCT02870036Phase 1Unknown
- Sponsor
- Haihe
- Start
- Oct 2016
- Primary completion
- Dec 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of simmitecan in solid tumor (advanced stage), colorectal cancer (CRC) and gastrointestinal tumor (6 arms), sponsored by Haihe. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 5 more. Status: unknown.
02
Drugs
simmitecan
03
Conditions
solid tumor (advanced stage)colorectal cancer (CRC)gastrointestinal tumor
Beyond the preview
Go deeper on NCT02870036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02870036.